CLBS - カラドリアス・バイオサイエンス (Caladrius Biosciences Inc.) カラドリアス・バイオサイエンス

 CLBSのチャート


 CLBSの企業情報

symbol CLBS
会社名 Caladrius Biosciences Inc (カラドリアス・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Hospital/Nursing Management  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Caladrius Biosciences Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company''s lead product candidate CLBS03 is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient''s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study a Phase II prospective randomized placebo-controlled double-blind clinical trial to evaluate its Treg product candidate CLBS03 in adolescents with recent onset T1D. The Company plans to develop its product candidate CLBS12 in Japan which is an autologous therapy that derives its cells from peripheral blood through apheresis.   カラドリアス・バイオサイエンスは米国のバイオテクノロジ―企業。独自の細胞治療製品の開発に従事し、再生医療分野でのサ―ビスを提供する。虚血に対処するための治療法の開発、急性心筋梗塞後の損傷した心筋を治療、免疫系の不均衡によって引き起こされる疾患を治療、テクノロジ―再生医療プラットフォ―ムなどがある。   Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
本社所在地 106 Allen Road Fourth Floor Basking Ridge NJ 07920 USA
代表者氏名 David J. Mazzo デビットJ.マッツォ
代表者役職名 Chief Executive Officer Independent Director
電話番号 +1 908-842-0100
設立年月日 29465
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 221人
url https://www.caladrius.com/
nasdaq_url https://www.nasdaq.com/symbol/clbs
adr_tso
EBITDA EBITDA(百万ドル) -22.53046
終値(lastsale) 5.01
時価総額(marketcap) 48724464.42
時価総額 時価総額(百万ドル) 44.34802
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -5.95137
当期純利益 当期純利益(百万ドル) 13.58047
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Caladrius Biosciences Inc revenues was not reported. Net loss before extraordinary items increased 5% to $9.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.95.

 CLBSのテクニカル分析


 CLBSのニュース

   Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer  2021/09/01 12:00:00 Intrado Digital Media
BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Companys Chief Medical Officer (CMO).
   Caladrius Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/16 19:45:54 Seeking Alpha
   Investors Focused Stock: Barrick Gold Corporation (NYSE:GOLD), Caladrius Biosciences, Inc. (NASDAQ:CLBS)  2021/08/09 21:58:25 Stock Equity
Barrick Gold Corporation (GOLD) with the stream of -1.73% also noticed, India Caladrius Biosciences, Inc. (CLBS) encountered a rapid change of 3.15% in the last hour of Mondays trading session. The post Investors Focused Stock: Barrick Gold Corporation (NYSE:GOLD), Caladrius Biosciences, Inc. (NASDAQ:CLBS) appeared first on Stocks Equity .
   Caladrius Biosciences EPS beats by $0.04  2021/08/05 20:12:36 Seeking Alpha
   Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/05 20:05:00 Intrado Digital Media
Conference call begins today at 4:30 p.m. Eastern Time Conference call begins today at 4:30 p.m. Eastern Time
   Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development  2021/05/12 18:15:16 Benzinga
Caladrius Biosciences Inc (NASDAQ: CLBS ) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying … Full story available on Benzinga.com
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
   Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?  2021/03/08 14:13:02 Yahoo Finance
Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.
   Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease  2021/03/08 13:00:00 GlobeNewswire
BASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…
   54 Biggest Movers From Yesterday - Stocks News Feed  2021/01/21 10:03:57 Stocks News Feed
Gainers Obalon Therapeutics Inc (NASDAQ: OBLN) shares jumped 414.3% to close at $8.28 on Wednesday after the company announced a merger agreement with ReShape Lifesciences. Steel Connect, Inc. (NASDAQ: STCN) gained 79.2% to close at $2.67 after climbing over 36% on Tuesday. Caladrius Biosciences, Inc. (NASDAQ: CLBS) shares gained 77.3% to close at $2.89. Caladrius… Read More »54 Biggest Movers From Yesterday

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラドリアス・バイオサイエンス CLBS Caladrius Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)